Crossing borders: factors affecting differences in cost-effectiveness of smoking cessation interventions between European countries.
OBJECTIVE
Many different factors affect the transferability of cost-effectiveness results between countries. The objective is to quantify the impact of nine potential causes of variation in cost-effectiveness of pharmacological smoking cessation therapies (SCTs) between The Netherlands (reference case), Germany, Sweden, UK, Belgium, and France.


METHODS
The life-time benefits of smoking cessation were calculated using the Benefits of Smoking Cessation on Outcomes model, following a cohort of smokers making an unaided quit attempt, or using nicotine replacement therapy (NRT), bupropion, or varenicline. We investigated the impact of between-country differences in nine factors-demography, smoking prevalence, mortality, epidemiology and costs of smoking-related diseases, resource use and unit costs of SCTs, utility weights and discount rates-on the incremental net monetary benefit (INMB), using a willingness-to-pay (WTP) of euro20,000 per quality adjusted life year (QALY).


RESULTS
The INMB of 1000 quit attempts with NRT versus unaided, varies from euro0.39 million (Germany) to euro1.47 million (France). The differences between the countries were primarily due to differences in discount rates, causing the INMB to change between -65% to +62%, incidence and mortality rates (epidemiology) of smoking-related diseases (-43% to +35%) and utility weights. Impact also depended on the WTP for a QALY and time horizon: at a low WTP or a short time horizon, the resource use and unit costs of SCTs had the highest impact on INMB.


CONCLUSIONS
Although all INMBs were positive, there were significant differences across countries. These were primarily related to choice of discount rate and epidemiology of diseases.
Vemer
Pepijn
P
Institute for Medical Technology Assessment (iMTA), Erasmus MC, Rotterdam, The Netherlands. vemer@bmg.eur.nl
Rutten-van Mölken
Maureen P M H
MP
D000293:Adolescent; D000328:Adult; D000368:Aged; D018687:Antidepressive Agents, Second-Generation / Q000191:economics / Q000627:therapeutic use; D001552:Benzazepines / Q000191:economics / Q000627:therapeutic use; D016642:Bupropion / Q000191:economics / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D003431:Cross-Cultural Comparison; D005060:Europe; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D018722:Nicotinic Agonists / Q000191:economics / Q000627:therapeutic use; D019057:Quality-Adjusted Life Years; D011810:Quinoxalines / Q000191:economics / Q000627:therapeutic use; D016540:Smoking Cessation / Q000191:economics* / Q000379:methods*; D000068580:Varenicline; D055815:Young Adult
D018687:Antidepressive Agents, Second-Generation; D001552:Benzazepines; D018722:Nicotinic Agonists; D011810:Quinoxalines; D016642:Bupropion; D000068580:Varenicline